17 January 2023 - - US-based early phase CRO Dr. Vince Clinical Research has administered the first dose of Aclaris Therapeutics' ATI-2138 in a Phase I multiple ascending dose study for an investigational oral compound being developed for the treatment of autoimmune diseases, the company said.

The Phase I MAD study in healthy volunteers is being conducted at DVCR's world-class clinical pharmacology unit.

The study will enroll 60 participants across five cohorts.

Many features of the facility were engineered specifically with the conduct of ascending dose trials in mind, including dedicated vital signs machines at every bedside to enhance data quality for dose escalation meetings and luxurious amenities to improve participant retention throughout the entire duration of the trial.

Dr. Vince Clinical Research looks forward to the successful completion of this trial and delivering on its promise to provide Smarter, Faster Data to its biopharmaceutical sponsors.

Dr. Vince Clinical Research is a world-class CRO (Contract Research Organization) with a custom-built, green-designed headquarters and research complex encompassing three buildings in Overland Park, KS.

DVCR's complex includes a 90-bed clinical pharmacology unit featuring a combination of luxurious and private research suites and a GMP compliant pharmacy with positive and negative pressure compounding rooms.

DVCR specializes in conducting clinical trials for both healthy normal volunteers and patient populations in a wide variety of early phase trials.

By leveraging both technology and one of the country's most experienced leadership teams, DVCR provides Smarter, Faster Data to their biopharmaceutical clients.